KR102282437B1 - Method for differentiation of fibroblast-like cells from human adipose derived stem cells - Google Patents

Method for differentiation of fibroblast-like cells from human adipose derived stem cells Download PDF

Info

Publication number
KR102282437B1
KR102282437B1 KR1020200152919A KR20200152919A KR102282437B1 KR 102282437 B1 KR102282437 B1 KR 102282437B1 KR 1020200152919 A KR1020200152919 A KR 1020200152919A KR 20200152919 A KR20200152919 A KR 20200152919A KR 102282437 B1 KR102282437 B1 KR 102282437B1
Authority
KR
South Korea
Prior art keywords
growth factor
stem cells
cells
differentiation
human adipose
Prior art date
Application number
KR1020200152919A
Other languages
Korean (ko)
Inventor
주지혜
Original Assignee
주식회사 래디안
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 래디안 filed Critical 주식회사 래디안
Priority to KR1020200152919A priority Critical patent/KR102282437B1/en
Priority to KR1020210064843A priority patent/KR20220066812A/en
Application granted granted Critical
Publication of KR102282437B1 publication Critical patent/KR102282437B1/en
Priority to PCT/KR2021/015841 priority patent/WO2022103065A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656Adult fibroblasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33Fibroblasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/06Plates; Walls; Drawers; Multilayer plates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/105Insulin-like growth factors [IGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/11Epidermal growth factor [EGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1384Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • C12N2533/54Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to a method for differentiating human adipose-derived stem cells into fibroblast-like cells using a plate coated with gelatin and containing a cell differentiation medium, and to a medium composition. The plate containing gelatin of the present invention can exert the effect of inducing direct cross-differentiation from human adipose-derived stem cells to fibroblasts, and efficiently performing mass culture in vitro at low cost by using economical materials. In addition, the fibroblast-like cells differentiated from human adipose-derived stem cells of the present invention can be used in a composition for alleviating skin wrinkles or scars.

Description

인간 지방 유래 줄기세포로부터 섬유아유사세포로의 분화방법 {Method for differentiation of fibroblast-like cells from human adipose derived stem cells}Method for differentiation of fibroblast-like cells from human adipose derived stem cells

본 발명은 젤라틴을 포함하는 분화유도용 세포 배양 플레이트에서 인간지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화 유도 배지 조성물을 이용하여 분화시키는 방법 및 상기 배지 조성물에 관한 것이다.The present invention relates to a method for differentiation inducing differentiation from human adipose-derived mesenchymal stem cells into fibroblast-like cells in a cell culture plate for inducing differentiation containing gelatin using a medium composition and the medium composition.

상처는 피부 표면의 파괴 유무에 따라, 피부나 점막이 손상되어 내부의 조직이 공기 중에 노출된 절상, 열상, 관통상, 찰과상 등의 개방성 상처(open wound), 및 피부나 점막의 파열은 없으나, 둔기로 인한 타박이나 비꼬임, 충격 당겨지거나, 꺾였을 때 발생할 수 있는 패쇄성 상처(closed wound)로 분류될 수 있다.Depending on whether the skin surface is destroyed or not, there are no open wounds such as cuts, lacerations, penetrating wounds, abrasions, etc. in which the skin or mucous membrane is damaged and the internal tissues are exposed to air, and there is no rupture of the skin or mucous membrane, but blunt It can be classified as a closed wound that can occur when bruised, twisted, impacted, pulled, or bent.

상처 치유(wound healing) 과정은 세포 내 인자에 의해 섬유아세포, 혈관내피세포(vascular endothelial cells), 케라티노사이트와 같은 외피세포(epidermal cells)가 증식을 개시하고, 상처 부위로 세포가 이동하여, 육아조직형성 (granulation tissue formation), 신생혈관형성 (angiogenesis) 및 재상피화 (reepithelization)의 과정을 거쳐 조직 재생이 이루어진다.In the wound healing process, epidermal cells such as fibroblasts, vascular endothelial cells, and keratinocytes initiate proliferation by intracellular factors, and the cells migrate to the wound site, Tissue regeneration occurs through the processes of granulation tissue formation, angiogenesis, and reepithelization.

상처 치유효능을 갖는 인자로는 EGF(epithelial growth factor), aFGF(acid fibroblast growth factor), bFGF(basic fibroblast growth factor), TGF(transforming growth factors) 및 IGF(insulin-like growth factors)와 같은 성장인자, 피브로넥틴(fibronectin), 라미닌(laminin) 및 비트로넥틴(vitronectin)과 같은 유착인자(adhesion factor), 레티노이드(retinoid)와 같은 화합물을 들 수 있다.Factors having a wound healing effect include epithelial growth factor (EGF), acid fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), transforming growth factors (TGF) and growth factors such as insulin-like growth factors (IGF). , adhesion factors such as fibronectin, laminin and vitronectin, and compounds such as retinoids.

상처가 회복되는 과정은 초기 창상 발생 후 동화(anabolic) 및 이화(catabolic) 과정이 6주 내지 8주간 균형적으로 일어나며, 이 단계에서 일반적으로 30% 내지 40%의 정상피부조직을 포함하는 회복 정도를 나타낸다. 상흔은 콜라겐 섬유가 점진적으로 교차 결합을 일으키면서 항장력(tensile strength)이 증가하여 충혈성의 융기된 상태로 형성되지만, 시간이 지나면서 점차 형태가 피부와 유사한 상태로 돌아간다. 상처 치유과정 중 동화 및 이화단계에서 상호 불균형이 발생한 경우에는 콜라겐이 분해되지 못하여 굳어져 흉터가 융기된 형태로 남아있게 되며, 이러한 조직은 융기형 흉터(hypertrophic scar) 또는 켈로이드(keloids)로 분류된다.In the wound healing process, anabolic and catabolic processes occur in a balanced way for 6 to 8 weeks after the initial wound, and in this stage, the degree of recovery that generally contains 30% to 40% of normal skin tissue indicates The scar is formed in a congested, raised state due to the increase in tensile strength as the collagen fibers gradually cross-link, but gradually returns to a skin-like state over time. In the case of an imbalance between the assimilation and catabolic stages during the wound healing process, the collagen cannot be decomposed and hardened and the scar remains in a raised form, and these tissues are classified as hypertrophic scars or keloids. .

상처 치유에 대한 관심과 이에 따른 여러 시술 또는 약물의 개발은 궁극적으로 흉터 생성을 예방하고자 하는 미용의 목적이 가장 크다. 흉터는 수술적 또는 비수술적 수단을 통하여 치료할 수 있으며, 비수술적 수단은 실리콘 겔, Cordran 및 Scarguard와 같은 밀폐 드레싱(occlusive dressings), 압박을 이용한 치료법, 콜라겐 형성을 억제하는 스테로이드 치료법 등이 있으며, 수술적 수단으로는 냉동치료, 레이저, 수술적 절제방법 등이 사용되고 있다. 수술에 의한 방법은 일반적으로 25% 내지 100%의 흉터 재발률을 나타내기 때문에, 실효성은 없는 것으로 알려져 있다. The interest in wound healing and the development of various procedures or drugs is ultimately the greatest goal of beauty to prevent scar formation. Scars can be treated through surgical or non-surgical means, and non-surgical means include silicone gel, occlusive dressings such as Cordran and Scarguard, treatment using compression, and steroid treatment to inhibit collagen formation. Cryotherapy, laser, and surgical excision methods are used as effective means. It is known that the surgical method is not effective because it generally shows a scar recurrence rate of 25% to 100%.

그 외에 흉터 부위에 국부적으로 인터페론 또는 베라파밀(verapamil), 블리오마이신(bleomycin), 5-FU(5-fluorouracil), 레티노산(retinoic acid), 이미퀴모드(imiquimod), 테크로리머스(tacrolimus) 또는 보튤리룸 톡신(botulinum toxin)을 주입하는 방법이 있으나, 이러한 방법 또한 치료 효율이 낮고, 흉터 재발률이 높으며, 약물투여에 의한 부작용 때문에 사용이 제한적인 단점이 있다.In addition, interferon or verapamil, bleomycin, 5-FU (5-fluorouracil), retinoic acid, imiquimod, tacrolimus Alternatively, there is a method of injecting botulinum toxin, but this method also has disadvantages of low treatment efficiency, high scar recurrence rate, and limited use due to side effects caused by drug administration.

상처 치유를 위한 한 방안으로 줄기세포를 이용하는 방안이 제안되고 있다. 줄기세포는 미분화 세포로서 자기 재생을 통해 오랫동안 분열을 할 수 있으며, 특정 환경 하에서는 다양한 종류의 세포로 분화할 수 있는 세포를 말한다. 줄기세포는 기원이 되는 조직에 따라 배아 줄기세포(embryonic stem cell)와 성체 줄기세포(adult stem cell)로 나누어진다. 이를 이용한 연구적인 측면에서 성체 줄기세포의 잠재 능력은 배아줄기세포보다 제한적인 단점이 있으나, 윤리적인 문제가 적어 성체 줄기세포를 대상으로 많은 연구가 진행되고 있다.A method using stem cells has been proposed as a method for wound healing. Stem cells are undifferentiated cells that can divide for a long time through self-renewal and can be differentiated into various types of cells under a specific environment. Stem cells are divided into embryonic stem cells and adult stem cells according to the tissue of origin. In terms of research using this, the potential of adult stem cells is limited compared to embryonic stem cells, but there are few ethical issues, so many studies are being conducted on adult stem cells.

중간엽 줄기세포(mesenchymal stem cells, MSCs)는 중간엽 기질세포(mesenchymal stromal cells)로도 불리는 다능성 세포(multipotent cell)이다. 중간엽 줄기세포는 골모세포, 연골모세포, 지방세포 등을 포함하는 다양한 형태의 세포로 분화될 수 있다.Mesenchymal stem cells (MSCs) are multipotent cells, also called mesenchymal stromal cells. Mesenchymal stem cells can be differentiated into various types of cells including osteoblasts, chondroblasts, adipocytes, and the like.

생체에서와는 달리 체외에서 인위적으로 동물 세포를 배양하기 위해서는, 혈장이나 림프액과 같은 체액을 근거로 한 생체 조건에 가까운 영양분과 pH, 온도, 삼투압 등의 환경 조건을 충분히 만족시켜 주어야 한다. 따라서, 체액을 근거로 배지 조성을 결정하고 이 결정된 배양 배지를 선택하여 혈청을 적정 비율로 세포에 맞게 첨가한 뒤 세포 배양에 이용하여 왔다. 이에 인간 줄기세포를 배양하기 위한 다양한 배지 조성물이 제시되고 있는데, 우태아혈청(FBS, Fetal Bovine Serum)과 같은 동물 혈청을 함유하는 배지를 이용하여 인간 줄기세포를 배양하는 방법이 통상적이다. Unlike in the living body, in order to artificially culture animal cells outside the body, nutrients close to the living conditions based on body fluids such as plasma or lymph and environmental conditions such as pH, temperature, and osmotic pressure must be sufficiently satisfied. Therefore, the medium composition was determined based on the body fluid, the determined culture medium was selected, serum was added to the cells at an appropriate ratio, and then used for cell culture. Accordingly, various medium compositions for culturing human stem cells have been proposed, and a method of culturing human stem cells using a medium containing animal serum such as Fetal Bovine Serum (FBS) is common.

하지만, 줄기세포의 분화과정은 다양한 요인에 의해 시일이 오래 소요되거나, 분화된 세포가 충분한 효과를 갖지 못하는 경우가 많다. However, the differentiation process of stem cells takes a long time due to various factors, or the differentiated cells do not have sufficient effects in many cases.

예를 들어, 하기 특허문헌 1의 경우에는 물리적 자극에 의한 세포 분화를 유도하고 있으나, 수주간의 in vitro 배양이 필요하므로 비용 및 대량생산 측면에서 적합하지 않다.For example, in the case of Patent Document 1 below, cell differentiation is induced by physical stimulation, but since in vitro culture for several weeks is required, it is not suitable in terms of cost and mass production.

한편, 요즘과 같이 환경의 변화나 생활패턴의 변화에 따른 냉난방의 인위적인 온도조절, 사회생활에서 발생되는 각종 스트레스와 환경오염으로 인한 피부 스트레스, 화장 습관에 따른 잦은 세안 및 연령 증가에 따른 자연적인 피부 노화 등의 여러 가지 원인으로 인하여 각질층의 수분이 감소하여 피부가 건조해지고 표면이 거칠게 되며 피부가 푸석거리고 촉촉함을 잃어 생기가 없어 보이는 등의 현상이 발생하기 때문에 피부 재생 및 주름 개선 등의 필요가 크게 증가하고 있다.On the other hand, as in these days, artificial temperature control of air conditioning and heating according to changes in the environment or life patterns, skin stress caused by various stresses and environmental pollution occurring in social life, frequent washing due to makeup habits, and natural skin due to increasing age Due to various causes such as aging, the moisture in the stratum corneum decreases, the skin becomes dry, the surface becomes rough, and the skin becomes brittle, loses moisture and looks lifeless. Therefore, there is a great need for skin regeneration and wrinkle improvement. is increasing

상기 줄기세포를 이용하여 상처를 치료하는 방안은 피부 재생에 도움이 되기 때문에, 미용 측면에서 피부 재생을 통한 흉터 및 주름 개선에도 도움이 될 수 있다는 점에 착안하여, 상처 치유와 흉터 및 주름개선에 효과적인 줄기세포의 경제적인 분화 방법 및 그 배지 조성물 등을 발명하게 되었다.Since the method of treating wounds using the stem cells is helpful for skin regeneration, focusing on the fact that it can also help improve scars and wrinkles through skin regeneration from a cosmetic point of view, it is useful for wound healing, scarring and wrinkle improvement. An effective method for economic differentiation of stem cells and a medium composition thereof were invented.

한국 특허등록번호 제1490235호Korean Patent Registration No. 1490235

본 발명은 상기 종래기술의 한계를 극복하기 위하여, 분화유도 기간을 단축함으로써 저비용으로 대량생산이 가능한 세포 분화방법 및 그 배지 조성물을 제공하는 것이다.In order to overcome the limitations of the prior art, it is an object of the present invention to provide a cell differentiation method capable of mass production at low cost by shortening the differentiation induction period, and a medium composition thereof.

본 발명에 따른 인간 지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화방법은, 젤라틴이 코팅된 플레이트에서 인간 지방 유래 중간엽 줄기세포를 배양하고, 교체가능한 세포분화용 배지를 부가하여, 섬유아유사세포로 분화시키는 것을 특징으로 한다.The method for differentiation from human adipose-derived mesenchymal stem cells to fibroblast-like cells according to the present invention comprises culturing human adipose-derived mesenchymal stem cells on a gelatin-coated plate, and adding a replaceable medium for cell differentiation, It is characterized in that it differentiates into subtype cells.

다른 일 구체예로서, 본 발명은 플레이트에 젤라틴이 코팅되고 세포분화용 배지가 부가된 것을 특징으로 하는 섬유아유사세포 분화 유도용 플레이트를 제공하는 것이다.In another embodiment, the present invention provides a plate for inducing differentiation of fibroblasts, characterized in that the plate is coated with gelatin and a medium for cell differentiation is added.

바람직하게는, 상기 세포분화용 배지는 전환성장인자(TGF-β: Transforming growth factor-β), 섬유아세포성장인자(FGF: Fibroblast growth factor), 덱사메타손(Dexamethasone), 결합조직성장인자(CTGF: Connective tissue growth factor), 인슐린성장인자(IGF: Insulin growth factor), 표피성장인자(EGF: Epidermal growth factor), 우태아혈청 및 페니실린/스트렙토마이신을 포함한다.Preferably, the cell differentiation medium is transforming growth factor (TGF-β: Transforming growth factor-β), fibroblast growth factor (FGF: Fibroblast growth factor), dexamethasone (Dexamethasone), connective tissue growth factor (CTGF: Connective) tissue growth factor), insulin growth factor (IGF), epidermal growth factor (EGF), fetal bovine serum and penicillin/streptomycin.

또한, 상기 플레이트가 인간 지방 유래 줄기세포로부터 섬유아유사세포로의 분화를 유도하기 위한 것이 바람직하다.In addition, it is preferable that the plate induces differentiation of human adipose-derived stem cells into fibroblasts.

또한, 상기 플레이트가 폴리스티렌(Polystyrene) 플레이트인 것이 바람직하다.In addition, it is preferable that the plate is a polystyrene plate.

또한, 상기 세포분화용 배지를 2~4일 간격으로 교체하는 것이 바람직하다.In addition, it is preferable to replace the cell differentiation medium every 2 to 4 days.

또한, 상기 세포분화용 배지를 2~7회 교체하는 것이 바람직하다.In addition, it is preferable to replace the cell differentiation medium 2 to 7 times.

본 발명의 또다른 구체예로서, 본 발명은, 상기 본 발명에 따른 분화방법 또는 플레이트를 이용하여 분화된 섬유아유사세포를 포함하는 피부 주름 또는 흉터 개선을 위한 위한 조성물을 제공하는 것이다.As another embodiment of the present invention, the present invention provides a composition for improving skin wrinkles or scars comprising fibroblast-like cells differentiated using the differentiation method or plate according to the present invention.

본 발명의 젤라틴을 포함하는 플레이트는 인간지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 직접교차분화를 유도하는 효과를 발휘할 수 있고, 경제적인 소재를 사용함으로써 저비용으로 체외에서 대량 배양을 효율적으로 가능하게 하는 효과를 발휘할 수 있다.The plate containing the gelatin of the present invention can exert the effect of inducing direct cross-differentiation from human adipose-derived mesenchymal stem cells to fibroblasts, and can efficiently perform mass culture in vitro at low cost by using economical materials. effect that makes it possible.

또한, 상기와 같이 분화된 섬유아유사세포는 피부 주름 또는 흉터 치료를 위한 세포치료제 조성물로 이용할 수도 있다.In addition, the differentiated fibroblast-like cells as described above can also be used as a cell therapy composition for the treatment of skin wrinkles or scars.

도 1은 본 발명에 따른 인간 지방 유래 중간엽 줄기세포의 확인 실험 결과를 개략적으로 도시한 것이다.
도 2 및 도 3는 분화 유도 방법으로 사용된 젤라틴 코팅 유무에 따른 마커 발현을 비교한 실험 결과를 개략적으로 도시한 것이다.
도 4 및 도 5는 인간 지방유래 줄기세포(ADSC)로부터 분화된 섬유아유사세포(dHDF)에 대하여 섬유아세포(HDF) 특이적 마커에 대한 유세포분석 (FACS)을 수행한 실험 결과를 개략적으로 도시한 것이다.
1 schematically shows the results of the confirmation experiment of human adipose-derived mesenchymal stem cells according to the present invention.
2 and 3 schematically show experimental results comparing marker expression with and without gelatin coating used as a differentiation induction method.
4 and 5 schematically show the experimental results of performing flow cytometry (FACS) for fibroblast (HDF)-specific markers on fibroblast-like cells (dHDF) differentiated from human adipose-derived stem cells (ADSC). did it

이하, 첨부된 도면을 참조하여 본 발명의 바람직한 실시 형태를 설명한다.Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings.

본 발명은 플레이트에 젤라틴이 코팅되고 세포분화용 배지가 부가된 것을 특징으로 하는 섬유아유사세포 분화 유도용 플레이트를 제공한다. The present invention provides a plate for inducing differentiation of fibroblasts, characterized in that the plate is coated with gelatin and a medium for cell differentiation is added.

본 발명에 따른 상기 플레이트는, 줄기세포의 분화 및 증식을 위해 적절한 세포외기질 분자를 사용하여야 한다. 사용할 수 있는 세포외기질 분자로는, 콜라겐(collagen), 피브로넥틴(Fibronectin), 마트리겔(Matrigel), 젤라틴(Gelatin) 등이 있으며, 본 발명에서는 바람직하게 세포의 분화 및 증식률이 가장 높았던 젤라틴을 사용하였고, 피더세포(feeder cell)를 포함하지 않고, 젤라틴이 코팅된 배양 플레이트를 사용하였다. 이를 통해 증식 및 분화를 위한 공배양 단계를 거치지 않기 때문에, 분화에 소요되는 시간을 단축하여 환자에게 신속한 적용이 가능하며, 피더세포(feeder cell)의 배양 과정에서 오염으로 인한 질병 전염 가능성을 낮추어 분화세포의 안정성을 높이는 효과를 얻게 된다.For the plate according to the present invention, an appropriate extracellular matrix molecule should be used for the differentiation and proliferation of stem cells. Examples of the extracellular matrix molecules that can be used include collagen, fibronectin, Matrigel, and gelatin. In the present invention, gelatin having the highest cell differentiation and proliferation rate is preferably used. and a culture plate coated with gelatin was used without including feeder cells. As it does not undergo a co-culture step for proliferation and differentiation, it can be applied quickly to patients by shortening the time required for differentiation, and it can be differentiated by reducing the possibility of disease transmission due to contamination during the culturing of feeder cells. It has the effect of increasing the stability of cells.

또한, 본 발명의 '젤라틴'이 코팅된 플레이트를 이용할 경우, 인간지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 직접교차분화를 유도하는 효과를 발휘할 수 있고, 경제적인 소재를 사용함으로써 저비용으로 체외에서 대량 배양을 효율적으로 가능하게 하는 효과를 발휘할 수 있다.In addition, when the plate coated with the 'gelatin' of the present invention is used, the effect of inducing direct cross-differentiation from human adipose-derived mesenchymal stem cells to fibroblast-like cells can be exerted, and the use of economical materials can help reduce costs. It is possible to exert the effect of efficiently enabling mass culture in vitro.

본 발명에 따른 상기 플레이트를 코팅하는 젤라틴은 다양한 농도의 젤라틴을 사용할 수 있으며, 바람직하게는 0.1 ~ 0.2 중량%인 것이 바람직하다. 상기 농도 범위 미만인 경우에는 젤라틴이 거의 코팅되지 않아 코팅 효과가 거의 없을 수 있으며, 반대로 상기 농도 범위를 초과하는 경우 코팅된 젤라틴의 두께가 지나치게 두껍거나 딱딱해져 세포 분화가 잘 일어나지 않는다. Gelatin for coating the plate according to the present invention may use various concentrations of gelatin, preferably 0.1 to 0.2% by weight. When the concentration is less than the concentration range, the gelatin is hardly coated and thus the coating effect may be almost absent. On the contrary, when the concentration range is exceeded, the thickness of the coated gelatin becomes too thick or hard, so that cell differentiation does not occur well.

한편, 본 발명에 따른 상기 플레이트는, 폴리스티렌 (Polystyrene) 플레이트인 것이 바람직하다.Meanwhile, the plate according to the present invention is preferably a polystyrene plate.

또한, 본 발명에 따른 상기 플레이트는, 바람직하게는 인간지방 유래 줄기세포로부터 섬유아유사세포로의 분화를 유도하기 위한 것일 수 있다.In addition, the plate according to the present invention may be for inducing differentiation from human adipose-derived stem cells into fibroblasts.

상기 인간지방 유래 줄기세포는, 바람직하게는 인간지방 유래 중간엽 줄기세포인 것이 좋다. 이때, 상기 중간엽 줄기세포는, 바람직하게는 골수, 지방조직 또는 탯줄에서 유래된 것일 수 있다.The human adipose-derived stem cells are preferably human adipose-derived mesenchymal stem cells. In this case, the mesenchymal stem cells, preferably, may be derived from bone marrow, adipose tissue or umbilical cord.

본 발명에 따른 인간 지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화방법은, 젤라틴이 코팅된 플레이트에서 인간 지방 유래 중간엽 줄기세포를 배양하고, 교체가능한 세포분화용 배지를 부가하여, 섬유아유사세포로 분화시키는 것을 포함한다.The method for differentiation from human adipose-derived mesenchymal stem cells to fibroblast-like cells according to the present invention comprises culturing human adipose-derived mesenchymal stem cells on a gelatin-coated plate, and adding a replaceable medium for cell differentiation, Differentiation into mimetic cells.

상기 세포분화용 배지는 전환성장인자(TGF-β: Transforming growth factor-β), 섬유아세포성장인자(FGF: Fibroblast growth factor), 덱사메타손(Dexamethasone), 결합조직성장인자(CTGF: Connective tissue growth factor), 인슐린성장인자(IGF: Insulin growth factor), 표피성장인자(EGF: Epidermal growth factor), 우태아혈청 및 페니실린/스트렙토마이신을 포함하는 것이 바람직하며, 당업계에서 동물세포 분화를 위해 사용되는 것이라면 어느 것이든 추가될 수 있다.The cell differentiation medium is transforming growth factor (TGF-β: Transforming growth factor-β), fibroblast growth factor (FGF: Fibroblast growth factor), dexamethasone (Dexamethasone), connective tissue growth factor (CTGF: Connective tissue growth factor) , insulin growth factor (IGF: Insulin growth factor), epidermal growth factor (EGF: Epidermal growth factor), preferably including fetal bovine serum and penicillin / streptomycin, any one used for animal cell differentiation in the art Anything can be added.

상기 세포분화용 배지에는, 바람직하게는 우태아혈청(FBS), 페니실린(penicillin) 및 스트렙토마이신 (streptomycin)이 첨가되어 조성된 것을 사용하는 것이 좋고, 더욱 바람직하게는 상용되는 DMEM/HIGH GLUCOSE 배지에 우태아혈청(FBS), 페니실린(penicillin) 및 스트렙토마이신 (streptomycin)이 첨가되어 조성된 것을 사용하는 것이 좋다.The cell differentiation medium is preferably formulated with fetal bovine serum (FBS), penicillin and streptomycin added, and more preferably in a commercially available DMEM/HIGH GLUCOSE medium. It is recommended to use a composition containing fetal bovine serum (FBS), penicillin and streptomycin.

본 발명의 세포분화용 배지에 포함되는 상기 우태아혈청은, 바람직하게는 5 ~ 15 %인 것이 좋으며, 더욱 바람직하게는 10 %인 것이 좋다.The fetal bovine serum contained in the cell differentiation medium of the present invention is preferably 5 to 15%, more preferably 10%.

또한, 본 발명의 세포분화용 배지에 포함되는 상기 페니실린/스트렙토마이신은, 바람직하게는 0.05 ~ 2 %인 것이 좋으며, 더욱 바람직하게는 1 %인 것이 좋다.In addition, the penicillin/streptomycin contained in the cell differentiation medium of the present invention is preferably 0.05 to 2%, more preferably 1%.

또한, 본 발명의 세포분화용 배지에 포함되는 상기 전환성장인자 (TGF-β: Transforming growth factor-β)는, 바람직하게는 10 ~ 20 ng/ml인 것이 좋고, 더욱 바람직하게는 15 ng/ml인 것이 좋다.In addition, the transforming growth factor (TGF-β: Transforming growth factor-β) contained in the cell differentiation medium of the present invention is preferably 10 to 20 ng/ml, more preferably 15 ng/ml it's good to be

또한, 본 발명의 세포분화용 배지에 포함되는 상기 섬유아세포성장인자 (FGF: Fibroblast growth factor)는, 바람직하게는 10 ~ 30 ng/ml인 것이 좋고, 더욱 바람직하게는 20 ng/ml인 것이 좋다.In addition, the fibroblast growth factor (FGF: Fibroblast growth factor) included in the cell differentiation medium of the present invention is preferably 10 to 30 ng/ml, more preferably 20 ng/ml .

또한, 본 발명의 세포분화용 배지에 포함되는 상기 덱사메타손 (Dexamethasone)은, 바람직하게는 0.05 ~ 0.2 nM인 것이 좋고, 더욱 바람직하게는 0.1 nM인 것이 좋다.In addition, the dexamethasone contained in the cell differentiation medium of the present invention is preferably 0.05 to 0.2 nM, more preferably 0.1 nM.

또한, 본 발명의 세포분화용 배지에 포함되는 상기 결합조직성장인자 (CTGF: Connective tissue growth factor)는, 바람직하게는 50 ~ 150 ng/ml인 것이 좋고, 더욱 바람직하게는 100 ng/ml인 것이 좋다.In addition, the connective tissue growth factor (CTGF) included in the cell differentiation medium of the present invention is preferably 50 to 150 ng/ml, more preferably 100 ng/ml good.

또한, 본 발명의 세포분화용 배지에 포함되는 상기 인슐린성장인자(IGF: Insulin growth factor)는, 바람직하게는 5 ~ 15 ng/ml인 것이 좋고, 더욱 바람직하게는 10 ng/ml인 것이 좋다.In addition, the insulin growth factor (IGF) contained in the cell differentiation medium of the present invention is preferably 5 to 15 ng/ml, more preferably 10 ng/ml.

또한, 본 발명의 세포분화용 배지에 포함되는 상기 표피성장인자(EGF: Epidermal growth factor)는, 바람직하게는 5 ~ 15 ng/ml인 것이 좋고, 더욱 바람직하게는 10 ng/ml인 것이 좋다.In addition, the epidermal growth factor (EGF) contained in the cell differentiation medium of the present invention is preferably 5 to 15 ng/ml, more preferably 10 ng/ml.

본 발명의 세포분화 방법은, 5% CO2 및 37℃의 온도에서 수행하였다. 이때, 세포 분화를 위한 최적 온도는 주로 세포가 분리된 숙주의 체온에 의존한 조건이고, 5% CO2는 세포 대사와 생장을 모니터링하기 위하여 양분이 한정된 배지에서 양분의 소모시기를 파악하기 위해 첨가한 pH 지시약인 페놀 레드(Phenol red)의 정상적인 작용을 위해 세포 대사 과정에서 발생한 배지 중 CO2가 인큐베이터(Incubator) 내부로 기화되지 않게 하기 위한 조건이다.The cell differentiation method of the present invention was carried out at a temperature of 5% CO 2 and 37 °C. At this time, the optimal temperature for cell differentiation is a condition that mainly depends on the body temperature of the host from which the cells are separated, and 5% CO 2 is added to monitor the cell metabolism and growth to determine the time of nutrient consumption in the nutrient-limited medium. For the normal action of phenol red, a pH indicator, CO 2 in the medium generated during cell metabolism is a condition to prevent vaporization into the incubator.

본 발명에 따른 세포분화 기간은 5~14일 바람직하며, 본 발명에서는 7일간 분화시켰다.The cell differentiation period according to the present invention is preferably 5 to 14 days, and in the present invention, it was differentiated for 7 days.

본 발명에 따른 세포분화용 배지는 2~4일 간격으로 교체하는 것이 바람직하며, 본 발명에서는 3일 간격으로 교체하였다. 이는 배지의 신선함(fresh)을 유지하기 위한 목적이며, 분화배지에 같이 처리하는 인자의 경우 높은 온도에서 오래 유지될 때, 활성이 떨어지기 때문에 배지를 교체하여 사용하는 것이 좋다.The medium for cell differentiation according to the present invention is preferably replaced at intervals of 2 to 4 days, and in the present invention, it is replaced at intervals of 3 days. This is for the purpose of maintaining the freshness of the medium, and in the case of factors treated with the differentiation medium, when maintained at a high temperature for a long time, the activity decreases, so it is recommended to replace the medium.

기존 연구들에서는 다른 기원의 세포를 IPS 세포(IPS cell)로 유도한 뒤, 분화시키는 방법을 사용하였다. 하지만 본 발명은 상기 인간지방 유래 줄기세포로부터 섬유아유사세포로의 분화 유도 방법에 있어서, 중간엽 줄기세포로부터 섬유아유사세포로 직접교차분화(Direct conversion, Trans-differentiation)시킨다는 점에서 특장점이 있다.In previous studies, cells of different origins were induced into IPS cells and then differentiated. However, in the method of inducing differentiation from human adipose-derived stem cells to fibroblasts, the present invention has a feature in that direct conversion (trans-differentiation) is performed from mesenchymal stem cells to fibroblasts. .

본 발명에 따라 인간 지방유래 줄기세포로부터 분화된 섬유아유사세포는 섬유아세포의 특이적 마커인 FSP-1 (Fibroblast-specific protein-1), CD91, CD55 및 CD10을 발현하는 것이다.The fibroblast-like cells differentiated from human adipose-derived stem cells according to the present invention express fibroblast-specific markers FSP-1 (Fibroblast-specific protein-1), CD91, CD55 and CD10.

후술하는 실험에 따르면, 본 발명에 따라 인간 지방유래 줄기세포로부터 분화된 섬유아유사세포(dHDF)는 인간 지방 유래 줄기세포 (ADSC)와 비교하여 섬유아세포 (HDF)의 특이적 마커인 FSP-1. CD91, CD55 및 CD10에 대해 양성인 세포의 비율이 90% 이상으로 확인되었으며, 이는 섬유아세포와 유사한 양상을 나타내었다.According to an experiment to be described later, fibroblast-like cells (dHDF) differentiated from human adipose-derived stem cells according to the present invention are compared with human adipose-derived stem cells (ADSC), FSP-1, a specific marker of fibroblasts (HDF). . The proportion of cells positive for CD91, CD55 and CD10 was found to be more than 90%, which was similar to that of fibroblasts.

상기와 같이, 본 발명은 인간지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 직접교차분화를 시키기 위한 젤라틴이 코팅된 플레이트와, 세포분화용 배지 조성물 및 이를 이용한 분화 방법을 통해 저비용으로 체외에서 대량 배양을 효율적으로 생산 가능하게 하는 효과를 발휘할 수 있으므로, 섬유아세포의 대체소재를 제공할 수 있다. 또한, 이러한 대체소재를 이용하여 피부 주름 또는 흉터 개선을 위한 위한 조성물 제공할 수 있다.As described above, the present invention provides a gelatin-coated plate for direct cross-differentiation from human adipose-derived mesenchymal stem cells into fibroblast-like cells, a cell differentiation medium composition, and a differentiation method using the same in vitro at low cost. Since it can exert the effect of enabling efficient mass culture production, it is possible to provide an alternative material for fibroblasts. In addition, it is possible to provide a composition for improving skin wrinkles or scars by using such an alternative material.

이하, 본 발명의 내용에 대해 하기 실시예 또는 실험예를 통해 더욱 상세히 설명하고자 한다.Hereinafter, the content of the present invention will be described in more detail through the following Examples or Experimental Examples.

아래 실시예에서는 인간지방 유래 줄기세포로부터 섬유아유사세포로의 분화 유도 및 상기 분화된 섬유아유사세포의 특성을 확인하였다.In the examples below, the induction of differentiation into fibroblasts from human adipose-derived stem cells and the characteristics of the differentiated fibroblasts were confirmed.

(실시예) (Example)

(1) 인간 지방 유래 중간엽 줄기세포의 확보(1) Securing of human adipose-derived mesenchymal stem cells

지방조직(고마바이오텍, Biopredic)을 인산완충용액으로 3회 세척하고 메스를 이용하여 1~3mm 크기로 자른다. 그 후, 0.075% collagenase type I으로 처리하여 37℃에서 shaking-waterbath에서 1시간 동안 반응시키고, 우태아혈청(FBS)이 10% 포함된 DMEM (Dulbecco's Modificaion of Eagle's Medium)배지로 중화시켜 배양용기로 이동시켜 부착시켰다. 세포가 배양 용기 표면의 80% 정도 증식이 되었을 때, Tryipin-EDTA를 처리하여 세포를 떼어내 2 x 105 cells per ml의 농도로 맞추어 줄기세포 양성 마커인 CD44 및 CD90와 음성마커 CD45의 항체와 30분간 반응시켰다. 염색시킨 세포를 착색 용액 (Staining solution)으로 세척하여 새로운 착색 용액(Staining solution)으로 세포를 현탁시킨 뒤, 유세포 측정기 (FACScalibur, BD science) 및 셀퀘스트 (CELLQUEST software; BD science)로 세포를 분석하였다.Adipose tissue (Goma Biotech, Biopredic) is washed three times with a phosphate buffer solution and cut into 1-3 mm pieces using a scalpel. After that, it was treated with 0.075% collagenase type I and reacted in a shaking-water bath at 37°C for 1 hour, neutralized with DMEM (Dulbecco's Modificaion of Eagle's Medium) medium containing 10% of fetal bovine serum (FBS), and put into a culture vessel. moved and attached. When the cells have proliferated about 80% of the surface of the culture vessel, the cells are removed by treatment with Tryipin-EDTA, adjusted to a concentration of 2 x 105 cells per ml, and the stem cell positive markers CD44 and CD90 and the negative marker CD45 antibodies and 30 reacted for minutes. The stained cells were washed with a staining solution, and the cells were suspended in a new staining solution, and then the cells were analyzed using a flow cytometer (FACScalibur, BD science) and Cellquest software (CELLQUEST software; BD science). .

그 결과, 도 1에 도시된 바와 같이, 상기 세포가 배양용기에 부착되고 줄기세포 양성 마커인 CD44 및 CD90가 발현되고, 조혈모세포 마커인 CD45가 거의 발현되지 않는 것을 확인함에 따라 지방 유래 줄기세포임을 확인하였다.As a result, as shown in FIG. 1 , it was confirmed that the cells were attached to the culture vessel, the stem cell positive markers CD44 and CD90 were expressed, and the hematopoietic stem cell marker CD45 was hardly expressed, indicating that the cells were adipose-derived stem cells. Confirmed.

(2) 인간 지방 유래 중간엽 줄기세포의 배양(2) Culture of human adipose-derived mesenchymal stem cells

상기에서 분리된 인간 지방 유래 중간엽 줄기세포를 기존 6 well plate (costar 사)와 젤라틴이 코팅된 폴리스티렌(polystyrene, PS) 플레이트 (6 well clear TC-treated Multiple Well Plates, 3516, Costar, Corning, NY, USA) (1 X 105 cells per well)에 배양하였다. 이때, 사용된 배지는 10% 우태아혈청(FBS) 및 1% 페니실린(penicillin)/스트렙토마이신(streptomycin)이 포함된 DMEM/HIGH GLUCOSE 배지 ((Dulbecco's Modified Eagle's Medium - High Glucose Liquid media (SH30243, Hyclone, UT, USA), 상세 배지 조성은 하기 표 1 참조)이며, 5% CO2 및 37℃의 온도조건에서 세포를 1일 배양하였다.The human adipose-derived mesenchymal stem cells isolated above were transferred to an existing 6 well plate (Costar) and a gelatin-coated polystyrene (PS) plate (6 well clear TC-treated Multiple Well Plates, 3516, Costar, Corning, NY). , USA) (1 X 10 5 cells per well). At this time, the medium used was DMEM/HIGH GLUCOSE medium ((Dulbecco's Modified Eagle's Medium - High Glucose Liquid media (SH30243, Hyclone) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin). , UT, USA), detailed medium composition is shown in Table 1 below), and cells were cultured for 1 day at 5% CO 2 and a temperature condition of 37°C.

Inorganic saltsorganic salts mg/Lmg/L mmol/Lmmol/L Calcium chlorideCalcium chloride 200200 1.80211.8021 Ferric nitrate-9H20Ferric nitrate-9H 2 0 0.10.1 0.00020.0002 Potassium chloridePotassium chloride 400400 5.36555.3655 Magnesium sulfateMagnesium sulfate 97.6797.67 0.81120.8112 Sodium chloridesodium chloride 64006400 109.514109.514 Sodium phosphate monobasic H20Sodium phosphate monobasic H 2 0 125125 0.90590.9059 Amino acidsamino acids mg/Lmg/L mmol/Lmmol/L L-Arginine-HClL-Arginine-HCl 8484 0.39870.3987 L-Cystine-2HClL-Cystine-2HCl 62.5762.57 0.19980.1998 L-GlutamineL-Glutamine 584584 3.99593.9959 GlycineGlycine 3030 0.39960.3996 L-Histidine-HCl-H20L-Histidine-HCl-H 2 0 4242 0.20040.2004 L-IsoleucineL-Isoleucine 104.8104.8 0.79890.7989 L-LeucineL-Leucine 104.8104.8 0.7990.799 L-Lysine-HClL-Lysine-HCl 146.2146.2 0.80040.8004 L-MethionineL-Methionine 3030 0.20110.211 L-PhenylalanineL-Phenylalanine 6666 0.39950.3995 L-SerineL-Serine 4242 0.39970.3997 L-ThreonineL-Threonine 95.295.2 0.79920.7992 L-TryptophanL-Tryptophan 1616 0.07830.0783 L-Tyrosine-2Na-2H20L-Tyrosine-2Na-2H 2 0 103.79103.79 0.39740.3974 L-ValineL-Valine 93.693.6 0.7990.799 VitaminsVitamins mg/Lmg/L mmol/Lmmol/L Calcium D-pantothenateCalcium D-pantothenate 44 0.00840.0084 D-Pantothenic acid Na saltD-Pantothenic acid Na salt 00 00 Choline chlorideCholine chloride 44 0.02860.0286 Folic acidfolic acid 44 0.00910.0091 Myo-inositolMyo-inositol 77 0.03890.0389 NiacinamideNiacinamide 44 0.03280.0328 Pyridoxine-HClPyridoxine-HCl 44 0.01950.0195 RiboflavinRiboflavin 0.40.4 0.00110.0011 Thiamine-HClThiamine-HCl 44 0.01190.0119 OtherOther mg/Lmg/L mmol/Lmmol/L D-GlucoseD-Glucose 45004500 24.977824.9778 HEPESHEPES 00 00 Phenol red-NaPhenol red-Na 15.915.9 0.04220.0422 Sodium pyruvateSodium pyruvate 110110 0.99960.9996 Sodium bicarbonateSodium bicarbonate 37003700 44.042444.0424

(3) 인간 지방 유래 줄기세포로부터 섬유아유사세포로의 분화 유도(3) Induction of differentiation from human adipose-derived stem cells to fibroblasts

젤라틴이 코팅된 플레이트(plate)에서 배양된 세포를 섬유아유사세포로 분화시키기 위해, 15 ng/ml 전환성장인자(TGF-β: Transforming growth factor-β), 20 ng/ml 섬유아세포성장인자(FGF: Fibroblast growth factor), 0.1 nM 덱사메타손(Dexamethasone), 100 ng/ml 결합조직성장인자(CTGF: Connective tissue growth factor), 10 ng/ml 인슐린성장인자(IGF: Insulin growth factor), 10 ng/ml 표피성장인자(EGF: Epidermal growth factor), 10% 우태아혈청 및 1% 페니실린/스트렙토마이신이 첨가된 DMEM/HIGH GLUCOSE 세포분화용 배지에서 5% CO2 및 37℃의 온도로 6 well plate 기준 2 ml를 취하여 7일간 배양하였다. 배지 교체는 3일에 한번씩 교체하였으며, 기존 배양배지를 제거(suction)한 뒤, 파이펫을 이용하여 DMEM/HIGH GLUCOSE 분화배지 2 ml로 교체하였다.In order to differentiate cells cultured in gelatin-coated plates into fibroblasts, 15 ng/ml Transforming growth factor-β (TGF-β), 20 ng/ml fibroblast growth factor ( FGF: Fibroblast growth factor), 0.1 nM dexamethasone, 100 ng/ml Connective tissue growth factor (CTGF), 10 ng/ml Insulin growth factor (IGF), 10 ng/ml In DMEM/HIGH GLUCOSE cell differentiation medium supplemented with epidermal growth factor (EGF), 10% fetal bovine serum and 1% penicillin/streptomycin, 5% CO 2 and a temperature of 37°C for 6 well plate 2 ml and cultured for 7 days. The medium was replaced once every 3 days, and after removing the existing culture medium (suction), it was replaced with 2 ml of DMEM/HIGH GLUCOSE differentiation medium using a pipette.

(비교예)(Comparative example)

상기 실시예에서 젤라틴이 코팅되지 않은 플레이트를 사용한 점을 제외하고는, 실시예와 동일하게 배양 및 분화시켰다.Culture and differentiation were carried out in the same manner as in Example, except that a plate not coated with gelatin was used in the above example.

(실험예 1) 젤라틴 코팅 유무에 따른 분화율 비교(Experimental Example 1) Comparison of differentiation rate with or without gelatin coating

상기 비교예에서 분화된 섬유아유사세포(non-coated)와 인간 지방 유래 줄기세표(ADSC) 및 섬유아세포(HDF)의 분화능을 비교하고자, 섬유아세포 특이적 마커인 FSP-1 (Fibroblast-specific protein-1) 및 CD10의 마커 발현을 유세포분석(FACS)을 통해 확인하였다.In order to compare the differentiation capacity of the differentiated fibroblast-like cells (non-coated) and human adipose-derived stem cells (ADSC) and fibroblasts (HDF) in the comparative example, the fibroblast-specific marker FSP-1 (Fibroblast-specific protein) -1) and CD10 marker expression was confirmed by flow cytometry (FACS).

상기 비교예에서 분화시킨 섬유아유사세포(non-coated), 인간 지방 유래 줄기세포(ADSC) 및 섬유아세포(HDF)를 0.05% 트립신/0.02% EDTA를 처리하여 세포를 떼어낸 후, 2 x 105 cells per ml의 농도로 맞추었으며, 세포용액을 Fc receptors blocking하였다. Fibroblast-like cells (non-coated), human adipose-derived stem cells (ADSC) and fibroblasts (HDF) differentiated in the comparative example were treated with 0.05% trypsin/0.02% EDTA to remove the cells, and then 2 x 10 The concentration was adjusted to 5 cells per ml, and the cell solution was blocked by Fc receptors.

(1) 그 뒤 FSP-1의 경우에는, Fixation/Permeabilization solution kit (BDCytofix/Cytoperm™ 社) kit의 고정용액(Fixation solution)을 이용하여 세포를 고정시켰으며, (2) CD10의 경우에는, CD10의 항체와 30분간 반응시킨 후,(1) After that, in the case of FSP-1, the cells were fixed using the Fixation/Permeabilization solution kit (BDCytofix/Cytoperm™) kit, (2) in the case of CD10, CD10 After reacting with the antibody of

염색시킨 세포를 착색 용액(Staining solution)으로 세척하여 새로운 착색 용액(Staining solution)으로 세포를 현탁시킨 뒤, 유세포 측정기 (FACScalibur, BD science) 및 셀퀘스트(CELLQUEST software; BD science)로 세포를 분석하였다.The stained cells were washed with a staining solution and the cells were suspended in a new staining solution, and then the cells were analyzed with a flow cytometer (FACScalibur, BD science) and Cellquest software (CELLQUEST software; BD science). .

도 2 및 도 3에 도시된 바와 같이, 같은 배지 조성을 이용하여 젤라틴 코팅 코팅이 되지 않은 플레이트에 적용시 분화가 거의 진행되지 않음을 확인하였다.As shown in Figures 2 and 3, it was confirmed that differentiation hardly proceeds when applied to a plate not coated with gelatin coating using the same medium composition.

(실험예 2) 유세포분석(FACS)을 통한 인간 지방 유래 줄기세포에서 분화된 섬유아유사세포 특성 확인(Experimental Example 2) Confirmation of characteristics of fibroblast-like cells differentiated from human adipose-derived stem cells through flow cytometry (FACS)

인간 피부 섬유아세포와 유사한 특성을 나타내는지 확인하고자, 섬유아세포에서 특이적으로 발현되는 FSP-1 (Fibroblast-specific protein-1), CD91, CD55 및 CD10의 마커 발현을 실험예 1과 같은 유세포분석(FACS)을 이용하여 비교하였다.In order to confirm whether it exhibits similar characteristics to human skin fibroblasts, the expression of markers of FSP-1 (Fibroblast-specific protein-1), CD91, CD55 and CD10 specifically expressed in fibroblasts was analyzed by flow cytometry as in Experimental Example 1. FACS) was used for comparison.

상기 섬유아세포 특이 마커 발현을 확인한 결과, 도 4 및 도 5에 도시된 바와 같이, 분화된 섬유아유사세포(dHDF)가 인간 지방유래 줄기세포 (ADSC)와 비교하여 섬유아세포 (HDF) 특이적 마커인 FSP-1. CD91, CD55 및 CD10에 대해 양성인 세포의 비율이 90% 이상으로 확인되었으며, 이는 섬유아세포와 유사하거나 더 높은 발현을 나타내는 것으로 확인되었다.As a result of confirming the expression of the fibroblast-specific marker, as shown in FIGS. 4 and 5 , differentiated fibroblast-like cells (dHDF) compared to human adipose-derived stem cells (ADSC) are fibroblast (HDF)-specific markers. In FSP-1. It was confirmed that the proportion of cells positive for CD91, CD55 and CD10 was more than 90%, which was confirmed to exhibit similar or higher expression to fibroblasts.

이상에서 본 발명의 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고, 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and variations are possible within the scope without departing from the technical spirit of the present invention described in the claims. It will be apparent to those of ordinary skill in the art.

Claims (12)

젤라틴이 코팅된 플레이트에서 인간 지방 유래 중간엽 줄기세포를 배양하고, 교체가능한 세포분화용 배지를 부가하여, 섬유아유사세포로 분화시키는 방법으로서,
상기 세포분화용 배지가 전환성장인자(TGF-β: Transforming growth factor-β), 섬유아세포성장인자(FGF: Fibroblast growth factor), 덱사메타손(Dexamethasone), 결합조직성장인자(CTGF: Connective tissue growth factor), 인슐린성장인자(IGF: Insulin growth factor), 표피성장인자(EGF: Epidermal growth factor), 우태아혈청 및 페니실린/스트렙토마이신을 포함하는 것을 특징으로 하는, 인간 지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화방법.
A method of culturing human adipose-derived mesenchymal stem cells on a gelatin-coated plate and adding a replaceable medium for cell differentiation to differentiate them into fibroblast-like cells, the method comprising:
The cell differentiation medium is transforming growth factor (TGF-β: Transforming growth factor-β), fibroblast growth factor (FGF: Fibroblast growth factor), dexamethasone (Dexamethasone), connective tissue growth factor (CTGF: Connective tissue growth factor) , Insulin growth factor (IGF), epidermal growth factor (EGF), fetal bovine serum and penicillin/streptomycin, characterized in that it contains fibroblasts from human adipose-derived mesenchymal stem cells Method of differentiation into cells.
삭제delete 제 1 항에 있어서, 상기 세포분화용 배지를 2~4일 간격으로 교체하는 것을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화방법.The method of claim 1, wherein the cell differentiation medium is replaced every 2 to 4 days from human adipose-derived mesenchymal stem cells to fibroblast-like cells. 제 1 항에 있어서, 상기 세포분화용 배지를 2~7회 교체하는 것을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터 섬유아유사세포로의 분화방법.The method according to claim 1, wherein the medium for cell differentiation is replaced 2 to 7 times from human adipose-derived mesenchymal stem cells to fibroblast-like cells. 삭제delete 젤라틴이 코팅되고 세포분화용 배지가 부가된 플레이트로서,
상기 세포분화용 배지가 전환성장인자(TGF-β: Transforming growth factor-β), 섬유아세포성장인자(FGF: Fibroblast growth factor), 덱사메타손(Dexamethasone), 결합조직성장인자(CTGF: Connective tissue growth factor), 인슐린성장인자(IGF: Insulin growth factor), 표피성장인자(EGF: Epidermal growth factor), 우태아혈청 및 페니실린/스트렙토마이신을 포함하는 것을 특징으로 하는, 인간 지방 유래 중간엽 줄기세포로부터의 섬유아유사세포 분화 유도용 플레이트.
A plate coated with gelatin and added with a cell differentiation medium,
The cell differentiation medium is transforming growth factor (TGF-β: Transforming growth factor-β), fibroblast growth factor (FGF: Fibroblast growth factor), dexamethasone (Dexamethasone), connective tissue growth factor (CTGF: Connective tissue growth factor) , Insulin growth factor (IGF), epidermal growth factor (EGF), fibroblasts from human adipose-derived mesenchymal stem cells comprising fetal bovine serum and penicillin/streptomycin A plate for inducing cell-like differentiation.
삭제delete 제 6 항에 있어서, 상기 플레이트가 인간 지방 유래 줄기세포로부터 섬유아유사세포로의 분화를 유도하기 위한 것임을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터의 섬유아유사세포 분화 유도용 플레이트.The plate for inducing differentiation of fibroblasts from human adipose-derived mesenchymal stem cells according to claim 6, wherein the plate is for inducing differentiation into fibroblasts from human adipose-derived stem cells. 제 6 항에 있어서, 상기 플레이트가 폴리스티렌(Polystyrene) 플레이트인 것을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터의 섬유아유사세포 분화 유도용 플레이트.The plate for inducing differentiation of fibroblasts from human adipose-derived mesenchymal stem cells according to claim 6, wherein the plate is a polystyrene plate. 제 6 항에 있어서, 상기 세포분화용 배지를 2~4일 간격으로 교체하는 것을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터의 섬유아유사세포 분화 유도용 플레이트.The plate for inducing differentiation of fibroblasts from human adipose-derived mesenchymal stem cells according to claim 6, wherein the cell differentiation medium is replaced every 2 to 4 days. 제 6 항에 있어서, 상기 세포분화용 배지를 2~7회 교체하는 것을 특징으로 하는 인간 지방 유래 중간엽 줄기세포로부터의 섬유아유사세포 분화 유도용 플레이트.The plate for inducing differentiation of fibroblasts from human adipose-derived mesenchymal stem cells according to claim 6, wherein the medium for cell differentiation is replaced 2 to 7 times. 삭제delete
KR1020200152919A 2020-11-16 2020-11-16 Method for differentiation of fibroblast-like cells from human adipose derived stem cells KR102282437B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020200152919A KR102282437B1 (en) 2020-11-16 2020-11-16 Method for differentiation of fibroblast-like cells from human adipose derived stem cells
KR1020210064843A KR20220066812A (en) 2020-11-16 2021-05-20 Method for differentiation of fibroblast-like cells from human adipose derived stem cells
PCT/KR2021/015841 WO2022103065A1 (en) 2020-11-16 2021-11-04 Method for differentiating fibroblast-like cells from human adipose-derived stem cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200152919A KR102282437B1 (en) 2020-11-16 2020-11-16 Method for differentiation of fibroblast-like cells from human adipose derived stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210064843A Division KR20220066812A (en) 2020-11-16 2021-05-20 Method for differentiation of fibroblast-like cells from human adipose derived stem cells

Publications (1)

Publication Number Publication Date
KR102282437B1 true KR102282437B1 (en) 2021-07-26

Family

ID=77124750

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020200152919A KR102282437B1 (en) 2020-11-16 2020-11-16 Method for differentiation of fibroblast-like cells from human adipose derived stem cells
KR1020210064843A KR20220066812A (en) 2020-11-16 2021-05-20 Method for differentiation of fibroblast-like cells from human adipose derived stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210064843A KR20220066812A (en) 2020-11-16 2021-05-20 Method for differentiation of fibroblast-like cells from human adipose derived stem cells

Country Status (2)

Country Link
KR (2) KR102282437B1 (en)
WO (1) WO2022103065A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103065A1 (en) * 2020-11-16 2022-05-19 주식회사래디안 Method for differentiating fibroblast-like cells from human adipose-derived stem cells
KR20230139010A (en) 2022-03-25 2023-10-05 주식회사 래디안 Composition for anti-aging and anti-wrinkle effectively comprising fibroblast-like cells and its cultured medium
KR20240078838A (en) 2022-11-28 2024-06-04 주식회사 래디안 Composition for maintaing differentiation potency of differentiated fibroblast-like cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822215B2 (en) * 2008-06-20 2014-09-02 Escape Therapeutics, Inc. Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same
KR101490235B1 (en) 2011-05-31 2015-02-05 서울대학교산학협력단 Construct for tissue-reconstruction and method for preparing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102141641B1 (en) * 2020-01-31 2020-08-06 주식회사 래디안 Method for differentiation of dermal papilla cells from human adipose mesenchymal stem cells
KR102282437B1 (en) * 2020-11-16 2021-07-26 주식회사 래디안 Method for differentiation of fibroblast-like cells from human adipose derived stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822215B2 (en) * 2008-06-20 2014-09-02 Escape Therapeutics, Inc. Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same
KR101490235B1 (en) 2011-05-31 2015-02-05 서울대학교산학협력단 Construct for tissue-reconstruction and method for preparing the same
KR20150035684A (en) * 2011-05-31 2015-04-07 서울대학교산학협력단 Construct for tissue-reconstruction and method for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biomed Res Int. 2013:347618 (2013.)* *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103065A1 (en) * 2020-11-16 2022-05-19 주식회사래디안 Method for differentiating fibroblast-like cells from human adipose-derived stem cells
KR20230139010A (en) 2022-03-25 2023-10-05 주식회사 래디안 Composition for anti-aging and anti-wrinkle effectively comprising fibroblast-like cells and its cultured medium
KR20240078838A (en) 2022-11-28 2024-06-04 주식회사 래디안 Composition for maintaing differentiation potency of differentiated fibroblast-like cells

Also Published As

Publication number Publication date
KR20220066812A (en) 2022-05-24
WO2022103065A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
KR102282437B1 (en) Method for differentiation of fibroblast-like cells from human adipose derived stem cells
Cheng et al. The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities
EP1874921B1 (en) Transplantation of differentiated immature adipocytes and biodegradable scaffold for tissue augmentation
Li et al. Epithelial differentiation of human adipose-derived stem cells (hASCs) undergoing three-dimensional (3D) cultivation with collagen sponge scaffold (CSS) via an indirect co-culture strategy
EP2894218B1 (en) Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells
KR20090086260A (en) Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
AU2011208948B2 (en) Method for stem cell differentiation
CN114867347B (en) Storage or transport formulations of mesenchymal stem cells and methods of making and using the same
WO2021117900A1 (en) Composition and use thereof
KR20200143399A (en) Method for inducing or improving wound healing properties of mesenchymal stem cells
WO2023011251A1 (en) Rapid and efficient clinical grade pigment epithelium induction method, kit, and application
KR102141641B1 (en) Method for differentiation of dermal papilla cells from human adipose mesenchymal stem cells
CN113337458A (en) Method for improving yield and purity of pluripotent stem cells directionally induced cardiac muscle cells
US20140106448A1 (en) Methods of isolating cells
JP6721504B2 (en) Process for producing pluripotent stem and progenitor cells
CN111019886A (en) Novel sternness factor and method or culture system for culturing embryonic stem cells by using same
WO2013123607A1 (en) Serum-free in vitro cultivation method and culture medium for adult stem cells
CN111662864A (en) Method for differentiating umbilical cord mesenchymal stem cells into dermal stem cells through in-vitro induction
JP2006000059A (en) Method for promoting proliferation and differentiation of animal cell by using extracellular substrate
KR20190130394A (en) A composition for stimulating differentiation of stem cell comprising multi-layer graphene film and culture broth of progenitor cell
KR20180092523A (en) Serum-free medium additive composition and method for inducing chondrogenesis of mesenchymal stem cells
EP4134429A1 (en) Stem cell culturing method for promoting initial yield of stem cel.ls
JP7315184B2 (en) Method for inducing differentiation from pluripotent stem cells to epidermal keratinocytes
CN107058214A (en) The culture medium and cultural method of induced multi-potent stem cell directed differentiation kidney cell
WO2021227573A1 (en) Xeno-free culture medium and method for expansion of mesenchymal stem cells by means of using same

Legal Events

Date Code Title Description
AMND Amendment
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant